Characteristics of commercially insured adult population exposed and not exposed to Schedule II stimulants in 2020
| Schedule II stimulant | Not exposed | |
| Insured adults, no (%) | 276 223 (3.0) | 8 865 654 (97.0) |
| Sex | ||
| Male | 119 271 (2.7) | 4 299 018 (97.3) |
| Female | 156 952 (3.3) | 4 566 636 (96.7) |
| Age group (years) | ||
| 19–34 | 128 257 (4.6) | 2 680 706 (95.4) |
| 35–44 | 66 387 (3.4) | 1 889 361 (96.6) |
| 45–54 | 51 658 (2.4) | 2 128 239 (97.6) |
| 55–64 | 29 921 (1.4) | 2 167 348 (98.6) |
| Prescription claims, median (IQR) | ||
| Total prescriptions | 21 (12–36) | 4 (0–14) |
| CNS prescriptions | 12 (7–21) | 0 (0–1) |
Source: MarketScan Research Databases, 2019–2020, commercially insured adults, age 19–64 years. Schedule II stimulants include amphetamine and methylphenidate drug products.
CNS, central nervous system.